186 related articles for article (PubMed ID: 34414935)
21. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
[TBL] [Abstract][Full Text] [Related]
22. XRCC1 and XPD genetic polymorphisms and clinical outcomes of gastric cancer patients treated with oxaliplatin-based chemotherapy: a meta-analysis.
Zhang X; Jiang LP; Yin Y; Wang YD
Tumour Biol; 2014 Jun; 35(6):5637-45. PubMed ID: 24590266
[TBL] [Abstract][Full Text] [Related]
23. Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis.
Cao Z; Song J; Wang J; Guo X; Yu S; Dong W
PLoS One; 2014; 9(1):e85357. PubMed ID: 24465544
[TBL] [Abstract][Full Text] [Related]
24. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
Liu YP; Ling Y; Zhang YP; Liu BR
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
[TBL] [Abstract][Full Text] [Related]
25. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
Bao Y; Yang B; Zhao J; Shen S; Gao J
Int J Immunogenet; 2020 Oct; 47(5):443-453. PubMed ID: 32173978
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of Excision Repair Cross-Complementation Group 1 in the Response to Platinum-Based Chemotherapy in Esophageal Cancer: A Meta-Analysis.
Zhuo ZG; Zhu YK; Deng HY; Li G; Luo J; Alai GH; Lin YD
Oncol Res Treat; 2020; 43(4):160-169. PubMed ID: 31958797
[TBL] [Abstract][Full Text] [Related]
27. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer in a Chinese population.
Li J; Zuo X; Lv X; Kong F; Xu W; Yang S
Tumour Biol; 2014 Aug; 35(8):7569-74. PubMed ID: 24793015
[TBL] [Abstract][Full Text] [Related]
28. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
29. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.
Park SR; Kong SY; Nam BH; Choi IJ; Kim CG; Lee JY; Cho SJ; Kim YW; Ryu KW; Lee JH; Rhee J; Park YI; Kim NK
Br J Cancer; 2011 Mar; 104(7):1126-34. PubMed ID: 21364592
[TBL] [Abstract][Full Text] [Related]
30. Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer.
Chen ZH; Wang L; Luo LP
Genet Mol Res; 2014 Sep; 13(3):7484-91. PubMed ID: 25222248
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetic role of XRCC1 polymorphisms on the clinical outcome of gastric cancer patients with platinum-based chemotherapy: a systematic review and meta-analysis.
Xu J; Ma J; Zong HT; Wang SY; Zhou JW
Genet Mol Res; 2014 Mar; 13(1):1438-46. PubMed ID: 24634242
[TBL] [Abstract][Full Text] [Related]
32. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
33. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer.
Liu L; Li CH; Jin TF; Xu DY
Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
Li FY; Ren XB; Xie XY; Zhang J
Asian Pac J Cancer Prev; 2013; 14(12):7203-6. PubMed ID: 24460276
[TBL] [Abstract][Full Text] [Related]
35. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer.
Kang S; Ju W; Kim JW; Park NH; Song YS; Kim SC; Park SY; Kang SB; Lee HP
Exp Mol Med; 2006 Jun; 38(3):320-4. PubMed ID: 16819291
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy.
Li F; Xie X; Ren X; Zhang J
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1183-91. PubMed ID: 27100737
[TBL] [Abstract][Full Text] [Related]
37. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
38. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
39. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
40. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Yamada Y; Boku N; Nishina T; Yamaguchi K; Denda T; Tsuji A; Hamamoto Y; Konishi K; Tsuji Y; Amagai K; Ohkawa S; Fujita Y; Nishisaki H; Kawai H; Takashima A; Mizusawa J; Nakamura K; Ohtsu A
Ann Oncol; 2013 Oct; 24(10):2560-2565. PubMed ID: 23884439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
